Development and validation of a blood-based protein predictor of 20-year dementia risk from middle age
Background
In the US the number of individuals affected by dementia is expected to double by 2040. Thus, tools enabling identification of at-risk individuals earlier in disease progression, or before disease onset, are vital. Proteomics-driven risk stratification for dementia may enable the initiation of life-planning and/or elicit changes in modifiable lifestyle-related risk factors. Moreover, test results may facilitate enrichment of clinical trial enrollment, and ultimately as an aid in precision prescribing of preventative therapeutics. Therefore, we sought to develop and validate a blood-based protein-only predictor of 20-year dementia risk from middle age.
Method
Using modified-aptamer proteomics technology, SomaScan® Assay v4.0, we scanned ~5,000 proteins in 11,277 EDTA plasma samples from individuals aged 49-73 without known dementia at visit 3 blood draw of the Atherosclerosis Risk in Communities (ARIC) study, totaling ~56 million protein measurements. A total 1,305 incident dementia diagnoses occurred within 20 years of blood-draw. Time to dementia diagnosis events were modeled with protein measurements using machine learning methods in 70% of ARIC V3 as a training dataset. A model was selected based on performance in a 15% holdout sample subset and validated in the remaining 15% samples. In a subset of 3,852 individuals with known ApoE status, the performance of the proteomic model was compared to that of the predictive performance of risk genotype.
Result
A 25-feature protein-only accelerated-failure-time Weibull model was successfully developed to predict the probability of a dementia diagnosis within 20 years of blood draw. Model performance was measured using AUC, which was equal to 0.73, 0.73, and 0.70, in the training, model selection, and validation datasets, respectively. Based on predicted probabilities from the model, individuals were stratified into low, medium-low, medium-high, and high risk bins, with a 20-year event rate of 3.79% vs 35.58% in low vs high risk bins. Model performance was significantly superior to that of ApoE genotype.
Conclusion: We successfully developed a well calibrated protein-only model with a 10-fold dynamic range that predicts 20-y risk of a dementia diagnosis. Performance of the protein model out-performs leading genetic risk factors for dementia and given the exclusion of immutable factors it has the potential to monitor changing risk.
Authors
Clare Paterson, PhD,
Amy Zhang, PhD,
Rachel Ostroff, PhD,
Yolanda Hagar, PhD,
Kelsey Loupy, PhD
Stephen Williams, MD, PhD
SomaLogic, Boulder, CO, USA
Click below for a downloadable version of this poster
More posters
PosterComparison of Proteomic CV Risk to Established ASCVD 10-Year Risk Decision Points
The ASCVD pooled cohort equation (PCE) is well-established for CV risk assessment. Decision points for determining treatment plans are low, intermediate and high risk over 10 years, however this approach over and underestimates risk in certain subgroups. The validated CV Risk SomaSignal® Test (SST) provides 4-year risk probability of MACE allowing for timely assessment of risk, but the shorter timescale makes comparison to 10-year PCE risk less intuitive.
PosterStatin signature: using proteomics to detect pharmacological fingerprints
Using a previously described metacohort (n=5,575) of patients with increased CV risk, we hypothesized that PCE would stratify patients differently than the CV Risk SST, and that CV Risk score scaled to 10 years would yield an improved net reclassification index (NRI).
PosterUsing a proteomics-based cardiovascular risk test to identify systemic changes in a clinical trial of nonalcoholic fatty liver disease
Improvement in hepaKc inflammaKon, NAFLD acKvity score and fibrosis were associated with improved proteomic CV risk scores regardless of treatment provided.